Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients

Zhang, Jing; Ji, Chao; Cheng, Bo; Ruan, Shifan; Liu, Tao; Huang, Jinwen

doi:10.1097/cm9.0000000000001259

Cited by 3 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, thus far, post‐marketing data on the mid‐term and long‐term real‐life performance of secukinumab are limited, especially over the long term. Only few real‐life studies with short‐term follow‐up cases have been conducted to investigate the outcomes of secukinumab in China 3–5 …”

Section: Introductionmentioning

confidence: 99%

“…Only few real-life studies with short-term follow-up cases have been conducted to investigate the outcomes of secukinumab in China. [3][4][5] This study aimed to examine the efficacy, safety, and drug survival of secukinumab in patients with moderate-to-severe plaque psoriasis who were treated with secukinumab between May 2019 and March 2020 and followed up for over 52 weeks in China.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Wang

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Secukinumab, a full human immunoglobulin G1κ monoclonal antibody that targets interleukin‐17A, has demonstrated remarkable efficacy and appreciable tolerance in patients with moderate‐to‐severe psoriasis. However, data on its real‐life performance, particularly on drug survival in China are limited. To investigate the efficacy, safety, and drug survival of secukinumab in Chinese patients with psoriasis, we conducted a monocentric retrospective study of 66 patients with moderate‐to‐severe psoriasis to followed‐up for 52 weeks. At week 12, 86.4%, 57.6%, and 10.6% of the patients attained 75% improvement in psoriasis area and severity Index (PASI) score from baseline (PASI 75), PASI 90, and PASI 100 responses, respectively. The quality of life of patients markedly improved. The overall survival rate was 74.2%. Adverse events occurred in 30 patients (45.5%). The results revealed favorable efficacy, safety, and tolerability of secukinumab in the treatment of patients with psoriasis and provided data on drug survival in real‐life clinical setting in China for the first time.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Wang

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Currently, data on real‐world outcomes of secukinumab in Chinese patients with moderate to severe plaque psoriasis during COVID‐19 pandemic are limited, especially on large population‐based real‐world study. Only a few real‐world studies with small sample sizes have been conducted to investigate the efficacy of secukinumab in accordance with standard treatment 5–8 …”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Zhou

Yuan

Liu

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis, whereas data on a large cohort of Chinese patients in long‐term real‐world practice are limited. This was a single‐centre, uncontrolled, single‐arm, prospective, observational cohort study that included 254 psoriatic patients treated with secukinumab between September 2019 and December 2022. Demographic and clinical characteristics of patients, clinical response and adverse events were evaluated. The 75% improvement in Psoriasis Area and Severity Index score (PASI 75), PASI 90, and PASI 100 in the 300 mg secukinumab group at 12 weeks were 91.7%, 74.0% and 39.7% respectively, increasing to 94.5%, 74.5% and 47.6% at 52 weeks. High body mass index (BMI), previous exposure to biologic therapies and history of previous conventional systemic therapies were associated with lower rates of PASI response. During the study period, 68 patients reported 83 adverse events (AEs) and the most frequent AEs were eczematous lesions. Up to 14.5% patients withdrew treatment due to disease remission combined with inconvenient transportation during the COVID‐19 pandemic at 52 weeks. The rate of psoriasis exacerbation after COVID‐19 infection in patients treated with secukinumab was 24.3% (17/70). This real‐world study confirmed the high effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, with an acceptable safety profile.

show abstract

“…Secukinumab, an IL‐17A inhibitor, 18 is recommended in multiple guidelines, 18–21 including the 2021 Chinese Guidelines 19 for adults with moderate‐to‐severe plaque psoriasis. Secukinumab effectively treated psoriasis in clinical trials 22–24 and real‐world studies in China 25–29 …”

Section: Introductionmentioning

confidence: 99%

“…Secukinumab effectively treated psoriasis in clinical trials [22][23][24] and real-world studies in China. [25][26][27][28][29] Previous real-world studies in China [25][26][27][28][29] on secukinumab's effectiveness have consistently reported excellent treatment responses at week 12 since initiation (~90% of patients achieved a ≥75% reduction in Psoriasis Area and Severity Index [PASI] scores). In China, data on secukinumab's optimal treatment patterns, effectiveness, and safety in real-world settings are lacking.…”

Section: Introductionmentioning

confidence: 99%

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Ding,

Li,

Guan

et al. 2023

Clinical Translational Sci

View full text Add to dashboard Cite

Secukinumab is effective in treating patients with moderate‐to‐severe plaque psoriasis. However, most studies assessing its effectiveness in routine clinical settings in China are mostly single‐center studies with a limited sample size. The objective of this study was to assess secukinumab's efficacy, treatment patterns, and characteristics in patients with moderate‐to‐severe plaque psoriasis. This 24‐week, multicenter (n = 5) retrospective study analyzed the data of Chinese adult patients with moderate‐to‐severe plaque psoriasis who initiated secukinumab treatment between May 2019 and March 2020. The Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator's Global Assessment Modified 2011 (IGA mod 2011), and Dermatology Life Quality Index (DLQI) were assessed. Dermatologists documented the treatment dosage and modification reasons. Of the 244 secukinumab‐naïve patients, most were men (73.4%, 179/244) and weighed 60–90 kg (72.8%, 177/243). The mean (SD) age at secukinumab initiation was 38.1 (11.6) years, and the disease duration was 13.5 (7.9) years. Most patients (97.1%, 237/244) received secukinumab 300 mg. At weeks 4, 12, 16, and 24, the proportion of patients achieving PASI 75 (≥75% reduction from baseline) was 40.0%, 92.1%, 88.4%, and 88.9%, respectively; PASI 90 was 15.0%, 73.7%, 81.4%, and 68.3%, respectively; and PASI 100 was 8.7%, 40.8%, 58.1%, and 41.3%, respectively. During the same periods, BSA and IGA mod 2011 showed similar improvement trends. An increasing proportion of patients achieved DLQI of 0–1 (21.6%, 65.7%, 75.0%, and 80.3%, respectively). Treatment modification was highest at week 12. The average interval between two administrations after week 4 was 62.95 days. Secukinumab was highly effective in improving the PASI, IGA, BSA, and DLQI in Chinese patients with moderate‐to‐severe plaque psoriasis throughout the first 24 weeks. The treatment pattern for Chinese patients differs from that in the clinical guidelines.

show abstract

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients

Cited by 3 publications

References 4 publications

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Contact Info

Product

Resources

About